Gehlken Carolin, Suthahar Navin, Meijers Wouter C, de Boer Rudolf A
Department of Cardiology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands.
Department of Cardiology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands.
Heart Fail Clin. 2018 Jan;14(1):75-92. doi: 10.1016/j.hfc.2017.08.009.
Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3-centered diseases.
半乳糖凝集素-3在组织炎症、修复和纤维化过程中发挥作用。本文特别聚焦于心力衰竭(HF),在心力衰竭中,半乳糖凝集素-3已被证明是预后和风险分层的有用生物标志物,尤其是在射血分数保留的心力衰竭中。实验研究表明,半乳糖凝集素-3直接诱导心脏的病理重塑,因此被认为是心力衰竭中心脏纤维化发展的致病蛋白,具有潜在的相关临床意义。总之,半乳糖凝集素-3是心脏重塑和纤维化中的生物标志物和生物靶点,未来的研究将针对以半乳糖凝集素-3为中心的疾病。